6949 — Pell Bio Med Technology Co Cashflow Statement
0.000.00%
- TWD8.17bn
- TWD7.61bn
- TWD19.63m
Annual cashflow statement for Pell Bio Med Technology Co, fiscal year end - December 31st, TWD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -189 | -231 | -401 | -395 |
Depreciation | ||||
Amortisation | ||||
Non-Cash Items | 26.4 | 45.8 | 138 | 46.6 |
Unusual Items | ||||
Equity in Net Earnings/Losses | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | 24.5 | -6.59 | 37.6 | 41.5 |
Change in Accounts Receivable | ||||
Change in Inventories | ||||
Change in Prepaid Expenses | ||||
Change in Other Assets | ||||
Change in Accounts Payable | ||||
Change in Other Liabilities | ||||
Other Operating Cash Flow | ||||
Cash from Operating Activities | -108 | -161 | -180 | -260 |
Capital Expenditures | -14.5 | -8.49 | -16.5 | -264 |
Purchase of Fixed Assets | ||||
Purchase / Acquisition of Intangibles | ||||
Other Investing Cash Flow Items | 98.4 | -542 | -403 | 168 |
Sale of Fixed Assets | ||||
Sale/Maturity of Investment | ||||
Change in Net Investments | ||||
Purchase of Investments | ||||
Other Investing Cash Flow | ||||
Cash from Investing Activities | 83.9 | -551 | -420 | -95.5 |
Financing Cash Flow Items | — | 15 | 0 | 110 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | -5.23 | 769 | 595 | 615 |
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | -29.2 | 56.6 | -4.73 | 260 |